Phillip Md Et Al Frost Purchases 500,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock in a transaction dated Wednesday, December 11th. The shares were acquired at an average cost of $1.56 per share, with a total value of $780,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 212,411,477 shares in the company, valued at $331,361,904.12. This trade represents a 0.24 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 29th, Phillip Md Et Al Frost purchased 199,072 shares of OPKO Health stock. The stock was acquired at an average cost of $1.53 per share, with a total value of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The shares were bought at an average cost of $1.59 per share, for a total transaction of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were bought at an average price of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost purchased 280,183 shares of OPKO Health stock. The stock was bought at an average price of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Price Performance

NASDAQ:OPK traded up $0.03 during mid-day trading on Wednesday, reaching $1.59. 2,995,388 shares of the company were exchanged, compared to its average volume of 6,819,181. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The stock has a market cap of $1.09 billion, a PE ratio of -8.42 and a beta of 1.62. OPKO Health, Inc. has a 12 month low of $0.85 and a 12 month high of $1.75. The company has a fifty day moving average of $1.53 and a 200 day moving average of $1.47.

Institutional Trading of OPKO Health

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. CIBC Asset Management Inc increased its stake in shares of OPKO Health by 79.1% in the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 8,978 shares during the period. Hollencrest Capital Management boosted its holdings in OPKO Health by 14.0% in the second quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 11,020 shares during the last quarter. FMR LLC increased its position in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the period. Price T Rowe Associates Inc. MD increased its position in OPKO Health by 4.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock worth $536,000 after purchasing an additional 17,671 shares during the period. Finally, PFG Investments LLC raised its holdings in OPKO Health by 2.5% during the 2nd quarter. PFG Investments LLC now owns 960,965 shares of the biotechnology company’s stock worth $1,201,000 after purchasing an additional 23,700 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

Analysts Set New Price Targets

OPK has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Thursday, September 26th. Piper Sandler restated an “overweight” rating and issued a $3.00 price target on shares of OPKO Health in a research report on Tuesday, September 17th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.